Amgen stock dropped Wednesday despite a strong second quarter as investors look ahead to the next weight-loss readouts.

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales offset higher operating expenses due in part to development of experimental ...

Amgen has said MariTide could offer quicker weight loss, possibly better weight maintenance, and fewer shots than weekly injections such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

The American Diabetes Association Scientific Sessions, held in June, featured cutting-edge science, from new agents to treat ...

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that ...

Amgen has said MariTide could offer quicker weight loss, possibly better weight maintenance, and fewer shots than weekly injections such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.

Amgen is also down to attractive levels even without considering the upside potential of MariTide in obesity, type 2 diabetes and adjacent markets, and today’s data increase my confidence that ...

--Amgen today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide, an investigational antibody peptide conjugate subcutaneously administered monthly or ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

--Amgen today issued the following statement on the MariTide Phase 1 data. Amgen Forward-Looking Statements This communication contains forward-looking statements that are based on the current ...

Amgen shares closed at $287.87 on Wednesday, down about 9% from earlier this month, when analysts at Cantor Fitzgerald said their review of Phase 1 MariTide data showed a drop in bone mineral ...

Amgen has said MariTide could offer quicker weight loss, possibly better weight maintenance, and fewer shots than weekly injections such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.